JDD Report Makes the Case for Aggressive Early Action in Suspected NF

When imaging is unremarkable and skin findings are minimal, necrotizing fasciitis can be easy to miss — and catastrophic to overlook.¹ A case report published in the Journal of Drugs in Dermatology illustrates exactly that diagnostic challenge while also shedding light on the role of GAS M-protein variants in treatment failure, an issue the authors argue deserves broader clinical attention.²

The Case

The patient, a previously healthy 50-year-old woman, presented to the emergency department with 4 days of severe left thigh pain, limited weight-bearing, fever, fatigue, and diarrhea. She had no visible skin changes and no recalled trauma to the area. Notably, she had been treated approximately 10 days prior for tonsillitis with a course of amoxicillin/clavulanate — without throat culture confirmation of group A Streptococcus (GAS).

On exam, erythema of the left thigh was minimal. The patient was initially normotensive, but rapidly deteriorated into tachycardia and hypotension. Labs were notable for leukocytosis and acute kidney injury, though blood cultures were negative. Bedside ultrasound of the left thigh was unremarkable, and CT demonstrated only soft tissue edema — without the classic imaging hallmarks of necrotizing fasciitis.

Despite the absence of definitive imaging findings, the degree of pain disproportionate to cutaneous findings prompted surgical exploration. That decision proved critical: intraoperative findings confirmed early necrotizing fasciitis, with edema localized to the sartorius muscle but no overt necrosis. The site was lavaged, cultures were taken, and wounds were left open. Cultures ultimately grew GAS sensitive to penicillin and cephalosporins. The patient was discharged on oral cefuroxime after improving on IV antibiotics.

An Unexpected Relapse

Six days post-discharge, the patient was re-admitted with recurrent thigh pain. Repeat cultures confirmed GAS sensitivity to cefuroxime — the antibiotic she had been taking — raising an important clinical question: why had a sensitive pathogen failed to clear?

The authors attribute the failure to a highly virulent antigenic variant of the GAS M-protein, a hypervariable surface protein and key virulence factor that facilitates bacterial persistence by resisting phagocytosis by polymorphonuclear leukocytes. With more than 200 known serotypes, the M-protein's variability can significantly influence how efficiently GAS evades host immune defenses. Although M-protein mutation testing was not performed in this case, the authors note that 2 separate failures of oral antibiotics in a patient with no history of immunodeficiency pointed strongly toward this mechanism.

Successful eradication ultimately required 4 weeks of high-dose IV ceftriaxone (2 g twice daily) combined with oral linezolid. The patient resolved without sequelae.

Clinical Takeaways

Writing in the paper's discussion, the authors — including Dermatology Times editorial adivsory board member Adam Friedman, MD, of George Washington University — emphasize that front-line clinicians must maintain a high index of suspicion for necrotizing fasciitis when soft tissue pain is disproportionate to visible findings, even when imaging is negative. In early-stage disease, both CT and bedside ultrasound can fail to capture the extent of subcutaneous involvement; surgical exploration remains the definitive diagnostic tool.

The case also raises a practical consideration for clinicians managing apparent antibiotic failure in GAS infections: when a sensitive pathogen does not respond as expected, M-protein-driven immune evasion should enter the differential. In such scenarios, prolonged high-dose IV antibiotic therapy may be necessary to achieve full bacterial clearance. Emerging investigational approaches — including M-protein–targeted vaccines and intravenous immunoglobulins — are under evaluation but are not yet standard of care.

The authors conclude with a clinical maxim that frames the entire report: in necrotizing fasciitis, time is tissue. Early recognition and rapid intervention remain the most powerful tools available.

References

1. Kochkine S, Payne DL, Chung K, et al. Imaging of necrotizing fasciitis. Clin Imaging. 2024;116:110331. doi:10.1016/j.clinimag.2024.110331
2. Fung H, Tse V, Friedman A. Time is tissue: a representative case report highlighting the importance of early clinical diagnosis of necrotizing fasciitis. J Drugs Dermatol. 2026. doi: 10.36849/JDD.9406